ProShare Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$270M Buy
1,073,381
+34,281
+3% +$7.38M 0.39% 34
2026
Q1
$226M Buy
1,039,100
+6,126
+0.6% +$1.36M 0.33% 41
2025
Q4
$236M Sell
1,032,974
-156,611
-13% -$35.7M 0.42% 43
2025
Q3
$275M Sell
1,189,585
-25,387
-2% -$5.17M 0.58% 21
2025
Q2
$226M Sell
1,214,972
-67,522
-5% -$12.5M 0.45% 39
2025
Q1
$269M Buy
1,282,494
+20,001
+2% +$3.89M 0.61% 27
2024
Q4
$224M Buy
1,262,493
+10,064
+0.8% +$1.85M 0.51% 37
2024
Q3
$247M Sell
1,252,429
-57,255
-4% -$10.7M 0.61% 30
2024
Q2
$225M Buy
1,309,684
+26,088
+2% +$4.32M 0.6% 28
2024
Q1
$234M Sell
1,283,596
-50,834
-4% -$8.76M 0.62% 29
2023
Q4
$207M Sell
1,334,430
-203,257
-13% -$29.6M 0.63% 34
2023
Q3
$229M Buy
1,537,687
+192,632
+14% +$28.3M 0.71% 22
2023
Q2
$181M Sell
1,345,055
-98,385
-7% -$14.4M 0.53% 57
2023
Q1
$230M Buy
1,443,440
+108,304
+8% +$16.6M 0.7% 19
2022
Q4
$216M Buy
1,335,136
+9,677
+0.7% +$1.48M 0.76% 23
2022
Q3
$178M Sell
1,325,459
-27,073
-2% -$3.88M 0.68% 26
2022
Q2
$207M Sell
1,352,532
-207,457
-13% -$31.7M 0.69% 23
2022
Q1
$253M Sell
1,559,989
-191,538
-11% -$27.8M 0.54% 29
2021
Q4
$237M Buy
1,751,527
+238,062
+16% +$28.1M 0.47% 35
2021
Q3
$163M Buy
1,513,465
+13,266
+0.9% +$1.52M 0.46% 50
2021
Q2
$169M Buy
1,500,199
+220,847
+17% +$24.9M 0.49% 36
2021
Q1
$138M Sell
1,279,352
-182,306
-12% -$19.5M 0.44% 46
2020
Q4
$157M Buy
1,461,658
+270,318
+23% +$26M 0.58% 27
2020
Q3
$104M Buy
1,191,340
+12,882
+1% +$1.21M 0.48% 52
2020
Q2
$116M Sell
1,178,458
-216,761
-16% -$19.1M 0.62% 26
2020
Q1
$106M Sell
1,395,219
-286,839
-17% -$24.4M 0.76% 20
2019
Q4
$149M Buy
1,682,058
+15,161
+0.9% +$1.26M 0.69% 26
2019
Q3
$126M Buy
1,666,897
+351,803
+27% +$24.1M 0.71% 23
2019
Q2
$95.6M Buy
1,315,094
+199,885
+18% +$15.7M 0.57% 41
2019
Q1
$89.9M Sell
1,115,209
-28,621
-3% -$2.34M 0.54% 44
2018
Q4
$105M Buy
1,143,830
+130,976
+13% +$11.5M 0.74% 22
2018
Q3
$95.8M Buy
1,012,854
+45,870
+5% +$4.35M 0.65% 28
2018
Q2
$89.6M Buy
966,984
+5,950
+0.6% +$581K 0.6% 29
2018
Q1
$91M Sell
961,034
-56,042
-6% -$6.16M 0.59% 30
2017
Q4
$98.4M Sell
1,017,076
-19,147
-2% -$1.8M 0.68% 24
2017
Q3
$92.1M Sell
1,036,223
-86,463
-8% -$6.58M 0.85% 15
2017
Q2
$81.4M Sell
1,122,686
-6,768
-0.6% -$455K 0.81% 15
2017
Q1
$73.6M Buy
1,129,454
+74,621
+7% +$4.69M 0.77% 20
2016
Q4
$66.1M Buy
1,054,833
+94,630
+10% +$5.78M 0.73% 23
2016
Q3
$60.6M Buy
960,203
+72,252
+8% +$4.68M 0.85% 20
2016
Q2
$55M Buy
887,951
+221,988
+33% +$13.5M 0.71% 28
2016
Q1
$38M Sell
665,963
-56,093
-8% -$3.13M 0.52% 34
2015
Q4
$42.8M Buy
722,056
+187,507
+35% +$10.8M 0.52% 36
2015
Q3
$29.1M Buy
534,549
+4,740
+0.9% +$309K 0.41% 51
2015
Q2
$35.6M Sell
529,809
-4,437
-0.8% -$290K 0.49% 37
2015
Q1
$31.3M Buy
534,246
+24,871
+5% +$1.5M 0.37% 54
2014
Q4
$33.3M Buy
509,375
+131,645
+35% +$8.3M 0.39% 48
2014
Q3
$21.8M Sell
377,730
-17,663
-4% -$981K 0.29% 62
2014
Q2
$22.3M Buy
395,393
+14,481
+4% +$760K 0.29% 59
2014
Q1
$19.6M Buy
380,912
+43,370
+13% +$2.19M 0.24% 67
2013
Q4
$17.8M Buy
337,542
+179,339
+113% +$8.81M 0.27% 67
2013
Q3
$7.08M Sell
158,203
-101,802
-39% -$4.51M 0.17% 93
2013
Q2
$10.7M Buy
+260,005
New +$11.4M 0.21% 84

Other funds holding ABBV

ProShare Advisors's ABBV Position: Q2 2026 in Review

ProShare Advisors increased its AbbVie (ABBV) stake by 3.3% in Q2 2026, buying an estimated $7.38M and bringing the position to 1,073,381 shares worth $270M. The position accounts for 0.39% of the portfolio, ranked #34.

ProShare Advisors first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. The position peaked at $275M in Q3 2025. 4,187 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • ProShare Advisors held 1,073,381 shares of AbbVie worth $270M as of Q2 2026.
  • ProShare Advisors bought 34,281 AbbVie shares in Q2 2026, an estimated $7.38M.
  • AbbVie made up 0.39% of ProShare Advisors's portfolio in Q2 2026, its #34 holding.
  • ProShare Advisors first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • ProShare Advisors's AbbVie position peaked at $275M in Q3 2025.
  • 4,187 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.